API

Mechanism of Action

XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase activity. Rivaroxaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation.

Indication

XARELTO is a factor Xa inhibitor indicated:

• To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
• For the treatment of deep vein thrombosis (DVT)
• For the treatment of pulmonary embolism (PE)  
• For the reduction in the risk of recurrence of DVT and/or PE in patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at least 6 months  
• For the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery